[Combination of anti-EGFR and anti-HER2 antibodies: hope in pancreatic cancer treatment] - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Bulletin du Cancer Year : 2007

[Combination of anti-EGFR and anti-HER2 antibodies: hope in pancreatic cancer treatment]

Abstract

Unresectable pancreatic cancer is still an extremely dismal prognosis. The conventional therapy using chemotherapy has no real effect on survival and new treatments are needed. EGFR and HER2 have been reported to be implicated and upregulated in pancreatic cancer tumorigenesis. The use of monoclonal antibodies (mAb) targeting these two receptors seems a relevant strategy for a new therapy. In a pre-clinical study, we demonstrated the therapeutic effect of the combination of two humanized Ab used in clinic, trastuzumab (Ab anti-HER2) and matuzumab (Ab anti-EGFR) in vivo in different carcinoma types. This Ab combination induced an important tumoral growth delay associated with some complete responses in two pancreatic carcinoma models expressing low HER2 level and in an ovarian model. Following all these results, a clinical trial is planned in pancreatic cancer.

Domains

Cancer Immunology
Fichier principal
Vignette du fichier
Larbouret_et_al.pdf (157.72 Ko) Télécharger le fichier
Fig1bdc.ppt (122.5 Ko) Télécharger le fichier
Format : Other
Loading...

Dates and versions

inserm-00192243 , version 1 (30-09-2008)

Identifiers

  • HAL Id : inserm-00192243 , version 1
  • PUBMED : 17964979

Cite

Christel Larbouret, Bruno Robert, Isabelle Teulon, Eric Assénat, David Azria, et al.. [Combination of anti-EGFR and anti-HER2 antibodies: hope in pancreatic cancer treatment]. Bulletin du Cancer, 2007, 94 (10), pp.860-2. ⟨inserm-00192243⟩
109 View
204 Download

Altmetric

Share

Gmail Facebook X LinkedIn More